Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors

1 Jan 2019

Abstract excerpt

In EGFR-treatment naive NSCLC patients, high-level MET amplification is detected in approximately 2–3% and is considered as adverse prognostic factor. Currently, clinical trials with two different inhibitors, capmatinib and tepotinib, are under way both defining different inclusion criteria regarding MET amplification from proven amplification only to defining an exact MET copy number. Here, 45 patient samples,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31762957
DOI: 10.1016/j.csbj.2019.09.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumorsPMID 31762957Read ↗

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsSemantic proximity Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.Semantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World SettingSemantic proximity Read ↗

A Novel Digital PCR Assay for Accurate Detection and Differentiation of Focal and Non-Focal Subtypes of <i>MET</i> Amplification in Lung CancerSemantic proximity Read ↗

Optimized NGS-based de novo MET amplification detection for improved lung cancer patient managementSemantic proximity Read ↗

Targeting MET in EGFR-Mutated NSCLC.Semantic proximity Read ↗

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.Semantic proximity Read ↗

Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancerSemantic proximity Read ↗

Overview of Molecular Detection Technologies for MET in Lung CancerSemantic proximity Read ↗

Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.